• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC)
【24h】

Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC)

机译：表皮生长因子受体（EGFR）的多态性与晚期头颈癌（HNSCC）患者的生存率

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aim: Associations between polymorphisms of the epidermal growth factor receptor (EGFR) and overall survival in patients with advanced carcinoma of the head and neck (HNSCC) receiving cetuximab based palliative treatment, were evaluated. Materials and Methods: HNSCC patients (n=48) received cetuximab +/- chemotherapy. Samples for DNA extraction and clinical data were collected prospectively. Genotyping of four EGF(R) polymorphisms was performed using PCR-based restriction fragment length polymorphism (RFLP). Results: The median overall survival was 10.6 months. The EGFR-R497K polymorphism was significantly associated with overall survival. The presence of at least one K-allele was associated with shorter overall survival. The median survival in these patients was 6.7 months compared to 13.3 months in the patients homozygous for the wild type allele EGFR-497R (p=0.009). Addition of chemotherapy to cetuximab, age and EGFR-R497K polymorphism were independent predictors of overall survival. Multivariate analysis revealed a hazard ratio (HR) for patients with at least one EGFR-497K allele of 3.03 when compared with EGFR-497R homozygous patients (p=0.045). Conclusion: The EGFR-R497K polymorphism is a potential predictor for overall survival in HNSCC patients treated with cetuximab based therapy in the palliative setting.
机译：目的：评估接受西妥昔单抗姑息治疗的晚期头颈癌（HNSCC）患者的表皮生长因子受体（EGFR）多态性与总生存率之间的关联。材料和方法：HNSCC患者（n = 48）接受西妥昔单抗+/-化疗。前瞻性收集DNA提取样品和临床数据。使用基于PCR的限制性片段长度多态性（RFLP）进行了四个EGF（R）多态性的基因分型。结果：中位总生存期为10.6个月。 EGFR-R497K多态性与总体生存率显着相关。至少一种K等位基因的存在与较短的总生存期有关。这些患者的中位生存期为6.7个月，而野生型等位基因EGFR-497R纯合的患者的中位生存期为13.3个月（p = 0.009）。西妥昔单抗，年龄和EGFR-R497K多态性之外的化疗是总体生存率的独立预测指标。多变量分析显示，与EGFR-497R纯合患者相比，至少有一个EGFR-497K等位基因为3.03的患者的危险比（HR）（p = 0.045）。结论：EGFR-R497K基因多态性是姑息治疗中以西妥昔单抗为基础治疗的HNSCC患者总体生存的潜在预测指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号